An article published by the Journal of the American Medical Association highlights recent updates made to the CONSORT ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

In this video interview, C.K. Wang, MD, chief medical officer, COTA, discusses how real-world data and real-world evidence ...

Approval is based on results from the Phase III ASCEND trial, in which patients using the powder achieved freedom from pain ...

Phase III trial data published in The New England Journal of Medicine support Nucala’s role as an add-on biologic therapy to ...

In this video interview, C.K. Wang, MD, chief medical officer, COTA, highlights cost and treatment sequencing as some of oncology’s largest hurdles.

Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior ...

Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in ...

In this video interview, C.K. Wang, MD, chief medical officer, COTA, shares his key takeaways from a recent study he led on data reporting in oncology and highlights how stakeholders should be closely ...